If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
Modified HGH fragment 176–191 (anti-obesity drug candidate)
Research documentation
AOD9604 is supplied for laboratory research. Contact sales to confirm the available identity, purity, and lot records, and discuss the evidence your assay or method-development project requires.
Overview
AOD9604 is a lipolytic peptide analog built from the C-terminal 176-191 region of human growth hormone, the segment thought to trigger fat-cell lipolysis through a mechanism independent of the GH receptor. It carries an extra N-terminal tyrosine — added to enable iodination for preclinical tracking — while the full-length HGH molecule's central anabolic regions are absent, so the fat-mobilizing activity is retained without the broader anabolic profile. Originating at Monash University in Australia, it reached Phase 2 obesity trials, did not gain regulatory approval, and subsequently moved into research-use and, in some jurisdictions, dietary-supplement channels. Lyochem supplies lyophilized AOD9604 to a ≥99.0% HPLC purity specification with a batch-specific COA available from sales. Every released lot comes with its batch COA covering RP-HPLC purity and ESI-MS confirmation of the tyrosine-modified mass; residual water is available on request and listed on the COA when tested. Since that N-terminal tyrosine is exactly what separates AOD9604 from the plain HGH Fragment 176-191, order placement should state which of the two is intended. Fills of 2, 5, and 10 mg span the usual research workflows.
Applications & buyer fit
GH-axis peptides ship to research labs studying somatotropic-pathway pharmacology and related models. Ask sales for the matching batch COA. Sequence, counter-ion, or stability evidence beyond that record is included only when required by a written project scope and agreed before quotation.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Biotech R&D Groups
Preclinical biotech and pharmaceutical discovery teams sourcing characterized peptides for receptor-pharmacology, screening, and method-development campaigns.
Every lot has its own batch-specific CoA — HPLC purity and MS identity, plus any analytical scope agreed at quote stage — tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration — Lyochem's GH-axis lots are scoped to research workflows only. Buyers studying somatotropic pharmacology should specify the counter-ion form (acetate by default) and any pulse-vs-sustained study design notes at quote stage.
Selected literature
Frequently asked questions
AOD9604 corresponds to the C-terminal region of GH, so identity work centers on confirming that specific fragment rather than any larger GH species. RP-HPLC establishes chemical purity and a characteristic retention profile, ESI-MS confirms the expected fragment mass and separates it from longer or truncated GH-derived sequences, and LC-MS/MS sequence verification, available on request, reads the residue ladder to confirm the intended C-terminal sequence. This matters because a mass in the right neighborhood is not proof of the correct fragment; full sequence coverage is what confirms the supplied material is the intended peptide and not a related GH-region species.
Like most synthetic peptides supplied as a salt, the vial mass is not all peptide, so the COA should distinguish gross fill weight from net peptide content after accounting for the counter-ion, typically acetate, and for bound water measured by Karl Fischer. Reporting the salt form and residual trifluoroacetate where relevant lets researchers dose by actual peptide mass instead of vial weight, which is essential when comparing lipolytic readouts across lots. Amino-acid analysis can anchor the net-content figure, and retaining a qualified reference aliquot supports lot-to-lot consistency checks over time.
Related peptides
16-mer
C-terminal fragment of human growth hormone (176–191)
29-mer
GHRH 1-29 fragment
Ghrelin / GHSR pathway GH-release peptide